NCT04357808View on ClinicalTrials.gov

Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

December 4, 2020

Conditions
Covid-19
Interventions
DRUG

Sarilumab

Single dose treatment with sarilumab 2 x 200 mg subcutaneously

OTHER

Standar of care

Usual clinical care

Trial Locations (1)

28006

Hospital Universitario de la Princesa, Madrid

All Listed Sponsors
collaborator

Instituto de Investigación Sanitaria Hospital Universitario de la Princesa

OTHER

lead

Maria del Rosario Garcia de Vicuña Pinedo

OTHER

NCT04357808 - Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) | Biotech Hunter | Biotech Hunter